51098-46-5

Basic information

• Product Name: Methyl 2-methylpyrrolidine-2-carboxylate hydrochloride
• Synonyms: Methyl 2-methylpyrrolidine-2-carboxylate hydrochloride;2-Methyl-DL-proline methyl ester HCl
• CAS NO: 51098-46-5
• Molecular Formula: C7H14ClNO2
• Molecular Weight: 179.64456
• Mol File: 51098-46-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 2-methylpyrrolidine-2-carboxylate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-methylpyrrolidine-2-carboxylate hydrochloride(51098-46-5)
• EPA Substance Registry System: Methyl 2-methylpyrrolidine-2-carboxylate hydrochloride(51098-46-5)

Safety Data

• Hazardous Substances Data: 51098-46-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Methyl 2-methylpyrrolidine-2-carboxylate hydrochloride is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Its unique structure and properties make it a valuable chemical intermediate for the development of various drugs and agrochemicals.
Used in Organic Chemistry:
Methyl 2-methylpyrrolidine-2-carboxylate hydrochloride is used as a building block in organic chemistry. Its versatile structure allows for the synthesis of a wide range of organic compounds, making it a valuable tool for chemists.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
Methyl 2-methylpyrrolidine-2-carboxylate hydrochloride is used as a chiral auxiliary in asymmetric synthesis. Its chiral center provides a unique opportunity for the development of enantioselective reactions, which are crucial for the synthesis of chiral compounds with specific biological activities.

Upstream product

• 317355-80-9 2-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 67-56-1 methanol 
• 1417560-84-9 (7aR)-7a-methyl-3-(trichloromethyl)tetrahydropyrrolo[1,2-c]oxazol-1(3H)-one 
• 63399-77-9 (R)-2-Methyl-1-azacyclopentan-2-carbonsaeure 
• 220200-88-4 (3R,7aS)-7a-methyl-3-(trichloromethyl)tetrahydropyrrolo[1,2-c]oxazol-1(3H)-one 
• 147-85-3 L-proline 
• 118916-60-2 (2R,5S)-2-trichloromethyl-1-aza-3-oxabicyclo[3.3.0]octan-4-one 
• 42856-71-3 (S)-2-methylpyrrolidine-2-carboxylic acid 

Downstream Products

• 853400-76-7 glycyl-L-2-methylprolyl-L-glutamic acid 
• 71922-04-8 (S)-1-nitrosopyrrolidine-2-carboxylic acid methyl ester 
• 1446261-55-7 (R)-methyl 11b-methyl-6-oxo-2,3,5,6,11,11b-hexahydro-1H-indolizino[8,7-b]indole-7-carboxylate 
• 1446261-61-5 (R)-methyl 9-fluoro-11b-methyl-6-oxo-2,3,5,6,11,11b-hexahydro-1H-indolizino[8,7-b]indole-7-carboxylate 
• 1446261-44-4 (10aR)-2-fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(7H)-one 
• 1417560-91-8 (R)-methyl 2-methyl-1-(3-(trifluoromethyl)benzyl)pyrrolidine-2-carboxylate 
• 1261569-85-0 (S)-8a-methyloctahydropyrrolo[1,2-a]pyrazine 
• 847952-36-7 (8aS)-8a-methylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione 
• 220060-17-3 (S)-1-tert-butyl 2-methyl 2-methylpyrrolidine-1,2-dicarboxylate 

Relevant articles and documents

Spatial Configuration and Three-Dimensional Conformation Directed Design, Synthesis, Antiviral Activity, and Structure-Activity Relationships of Phenanthroindolizidine Analogues

Our recent investigation on the antiviral activities against tobacco mosaic virus (TMV) of phenanthroindolizidine alkaloid analogues preliminarily revealed that the basic skeleton and substitution pattern at the C13a position of the molecule, which are cl

BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME

Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well a

Design and Synthesis of 56 Shape-Diverse 3D Fragments

Fragment-based drug discovery is now widely adopted for lead generation in the pharmaceutical industry. However, fragment screening collections are often predominantly populated with flat, 2D molecules. Herein, we describe a workflow for the design and synthesis of 56 3D disubstituted pyrrolidine and piperidine fragments that occupy under-represented areas of fragment space (as demonstrated by a principal moments of inertia (PMI) analysis). A key, and unique, underpinning design feature of this fragment collection is that assessment of fragment shape and conformational diversity (by considering conformations up to 1.5 kcal mol?1 above the energy of the global minimum energy conformer) is carried out prior to synthesis and is also used to select targets for synthesis. The 3D fragments were designed to contain suitable synthetic handles for future fragment elaboration. Finally, by comparing our 3D fragments with six commercial libraries, it is clear that our collection has high three-dimensionality and shape diversity.

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development

Poly (ADP-ribose) polymerase (PARP) plays a significant role in DNA repair responses; therefore, this enzyme is targeted by PARP inhibitors in cancer therapy. Here we have developed a number of fused tetra- or pentacyclic dihydrodiazepinoindolone derivatives with excellent PARP enzymatic and cellular PARylation inhibition activities. These efforts led to the identification of pamiparib (BGB-290, 139), which displays excellent PARP-1 and PARP-2 inhibition with IC50 of 1.3 and 0.9 nM, respectively. In a cellular PARylation assay, this compound inhibits PARP activity with IC50 = 0.2 nM. Cocrystal of pamiparib shows similar binding sites with PARP with other PARP inhibitors, but pamiparib is not a P-gp substrate and shows excellent drug metabolism and pharmacokinetics (DMPK) properties with significant brain penetration (17-19%, mice). The compound is currently being investigated in phase III clinical trials as a maintenance therapy in platinum-sensitive ovarian cancer and gastric cancer.

Chiral amination sulfoxide and preparation method thereof (by machine translation)

The invention belongs to the field of organic synthesis, and discloses chiral amination sulfoxide which has the structure of a general formula I. Wherein R is hydrogen or R1 And R2 Each independently selected from one of the following structures: hydrogen, alkyl, alkoxy, ester, trifluoromethyl, trifluoromethoxy, trifluoromethylthio. Halogens, alkynyl groups, alkenyl groups, amino groups, cyano groups, hydroxyl groups, aldehyde groups, carboxyl groups, nitro groups, amide groups, benzene rings, and bonded benzene ring fused rings to naphthalene; R3 Selected from the group consisting of phenyl, optionally substituted phenyl, aryl, heteroaryl, styryl, alkyl, haloalkyl and the like. The method comprises the following steps: forming a complex with a tert-butyl cyclopentadienyl metal iridium complex, forming a complex with the modified chiral proline, and activating C-H bond of enantioselective induced sulfoxide to obtain chiral sulphoxide. The synthetic method disclosed by the invention is high in yield and good in enantioselectivity, and the obtained amidated sulfoxide can be derivatized to obtain a chiral ligand. (by machine translation)

INTEGRIN ANTAGONISTS

The present disclosure provides therapeutic agents including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such therapeutic agents. Methods of using the therapeutic agents are also provided.

CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases. The present invention therefore relates to novel compounds which are selective antagonists of the EP4 subtype of PGE2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.

HETEROCYCLIC COMPOUND

An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING AUTISM SPECTRUM DISORDERS AND NEURODEVELOPMENTAL DISORDERS

Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autism Spectrum Disorders and Neurodevelopmental Diso

1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.